Literature DB >> 26371321

Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation.

Nadine Keleku-Lukwete1, Mikiko Suzuki2, Akihito Otsuki3, Kouhei Tsuchida3, Saori Katayama3, Makiko Hayashi3, Eriko Naganuma3, Takashi Moriguchi3, Osamu Tanabe4, James Douglas Engel5, Masue Imaizumi6, Masayuki Yamamoto7.   

Abstract

Sickle cell disease (SCD) is an inherited disorder caused by a point mutation in the β-globin gene, leading to the production of abnormally shaped red blood cells. Sickle cells are prone to hemolysis and thereby release free heme into plasma, causing oxidative stress and inflammation that in turn result in damage to multiple organs. The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is a master regulator of the antioxidant cell-defense system. Here we show that constitutive Nrf2 activation by ablation of its negative regulator Keap1 (kelch-like ECH-associated protein 1) significantly improves symptoms in SCD model mice. SCD mice exhibit severe liver damage and lung inflammation associated with high expression levels of proinflammatory cytokines and adhesion molecules compared with normal mice. Importantly, these symptoms subsided after Nrf2 activation. Although hemolysis and stress erythropoiesis did not change substantially in the Nrf2-activated SCD mice, Nrf2 promoted the elimination of plasma heme released by sickle cells' hemolysis and thereby reduced oxidative stress and inflammation, demonstrating that Nrf2 activation reduces organ damage and segregates inflammation from prevention of hemolysis in SCD mice. Furthermore, administration of the Nrf2 inducer CDDO-Im (2-cyano-3, 12 dioxooleana-1, 9 diene-28-imidazolide) also relieved inflammation and organ failure in SCD mice. These results support the contention that Nrf2 induction may be an important means to protect organs from the pathophysiology of sickle cell-induced damage.

Entities:  

Keywords:  Keap1; Nrf2; sickle cell disease

Mesh:

Substances:

Year:  2015        PMID: 26371321      PMCID: PMC4593117          DOI: 10.1073/pnas.1509158112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

2.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

3.  Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity.

Authors:  Hiromi Okawa; Hozumi Motohashi; Akira Kobayashi; Hiroyuki Aburatani; Thomas W Kensler; Masayuki Yamamoto
Journal:  Biochem Biophys Res Commun       Date:  2005-11-08       Impact factor: 3.575

4.  Patterns of mortality in sickle cell disease in the United Kingdom.

Authors:  A Gray; E N Anionwu; S C Davies; M Brozovic
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

5.  Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4.

Authors:  Osamu Tanabe; David McPhee; Shoko Kobayashi; Yannan Shen; William Brandt; Xia Jiang; Andrew D Campbell; Yei-Tsung Chen; Chawn shang Chang; Masayuki Yamamoto; Keiji Tanimoto; James Douglas Engel
Journal:  EMBO J       Date:  2007-04-12       Impact factor: 11.598

6.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

7.  Genetic analysis of cytoprotective functions supported by graded expression of Keap1.

Authors:  Keiko Taguchi; Jonathan M Maher; Takafumi Suzuki; Yukie Kawatani; Hozumi Motohashi; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

8.  Interaction of stem cell factor and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the murine spleen.

Authors:  V C Broudy; N L Lin; G V Priestley; K Nocka; N S Wolf
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

Review 9.  The role of junctional adhesion molecules in vascular inflammation.

Authors:  Christian Weber; Line Fraemohs; Elisabetta Dejana
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

10.  Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha.

Authors:  Brian N Chorley; Michelle R Campbell; Xuting Wang; Mehmet Karaca; Deepa Sambandan; Fatu Bangura; Peng Xue; Jingbo Pi; Steven R Kleeberger; Douglas A Bell
Journal:  Nucleic Acids Res       Date:  2012-05-11       Impact factor: 16.971

View more
  45 in total

1.  Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.

Authors:  Wanwisa Promsote; Folami Lamoke Powell; Satyam Veean; Menaka Thounaojam; Shanu Markand; Alan Saul; Diana Gutsaeva; Manuela Bartoli; Sylvia B Smith; Vadivel Ganapathy; Pamela M Martin
Journal:  Antioxid Redox Signal       Date:  2016-08-22       Impact factor: 8.401

2.  Nrf2 Signaling in Macrophages.

Authors:  Hong Zhu; Zhenquan Jia; Y Robert Li
Journal:  React Oxyg Species (Apex)       Date:  2016

3.  Defining ROS in Biology and Medicine.

Authors:  Robert Li; Zhenquan Jia; Michael A Trush
Journal:  React Oxyg Species (Apex)       Date:  2016

4.  Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.

Authors:  John D Belcher; Chunsheng Chen; Julia Nguyen; Ping Zhang; Fuad Abdulla; Phong Nguyen; Trevor Killeen; Pauline Xu; Gerry O'Sullivan; Karl A Nath; Gregory M Vercellotti
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

5.  Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.

Authors:  Nadine Keleku-Lukwete; Mikiko Suzuki; Harit Panda; Akihito Otsuki; Fumiki Katsuoka; Ritsumi Saito; Daisuke Saigusa; Akira Uruno; Masayuki Yamamoto
Journal:  Blood Adv       Date:  2019-04-23

Review 6.  Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.

Authors:  Xingguo Zhu; Aluya R Oseghale; Lopez H Nicole; Biaoru Li; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-23

Review 7.  Nuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart.

Authors:  Philipp Jakobs; Vlad Serbulea; Norbert Leitinger; Anna Eckers; Judith Haendeler
Journal:  Antioxid Redox Signal       Date:  2017-01-18       Impact factor: 8.401

Review 8.  Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.

Authors:  Angela Rivers; Ramasamy Jagadeeswaran; Donald Lavelle
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-01       Impact factor: 3.619

9.  Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice.

Authors:  Samit Ghosh; Chibueze A Ihunnah; Rimi Hazra; Aisha L Walker; Jason M Hansen; David R Archer; Amma T Owusu-Ansah; Solomon F Ofori-Acquah
Journal:  JCI Insight       Date:  2016-04-07

10.  Hepatic Overexpression of Hemopexin Inhibits Inflammation and Vascular Stasis in Murine Models of Sickle Cell Disease.

Authors:  Gregory M Vercellotti; Ping Zhang; Julia Nguyen; Fuad Abdulla; Chunsheng Chen; Phong Nguyen; Carlos Nowotny; Clifford J Steer; Ann Smith; John D Belcher
Journal:  Mol Med       Date:  2016-07-19       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.